Business roundup
28 November 2011 Business
Industry news, December 2011
Regorafenib approved in US
28 September 2012
US authorities have approved Stivarga (regorafenib) tablets for the treatment of advanced colorectal cancer. Specifically, regorafenib is to be used when cancer has progressed after treatment and spread to other parts of the body.
Regorafenib was licensed to Bayer in 2011 by US drug maker Onyx, which has already joined up with Bayer on another cancer drug, sorafenib, sold as Nexavar tablets. Regorafenib is a multi-kinase inhibitor that blocks several enzymes involved in cancer growth.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer in the US and the third leading cause of cancer death.
Related Content
India green lights production of patented cancer drug
20 March 2012 News and Analysis
For the first time India has invoked a 'compulsory licence' clause to cut the cost of a patented anti-cancer drug
Most Read
Growing a microgarden
17 May 2013 Research
Barium carbonate crystals have been coaxed to form nano-flowers by controlling their chemical environment
Sugar solution to toxic gold recovery
15 May 2013 Research
The environmental legacy of salvaging gold from electronic waste can be dramatically cut using corn starch instead of cyanide
Most Commented
DCD in New Zealand milk
31 January 2013 Business
Dicyandiamide poses no food risk but fertiliser companies have suspended sales
3D printer churns out bionic ear
17 May 2013 Research
Seamless integration of electronics and tissue could be used with other artificial implants and synthetic organs